Literature DB >> 18598019

Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.

Li Chen1, Yihua Zhang, Xiangwen Kong, Edward Lan, Zhangjian Huang, Sixun Peng, Daniel L Kaufman, Jide Tian.   

Abstract

Novel furoxan-based nitric oxide (NO) releasing derivatives of oleanolic acid (OA) were synthesized for potential therapy of liver cancers. Six compounds produced high levels of NO in human hepatocellular carcinoma (HCC) cells and exhibited strong cytotoxicity selectively against HCC in vitro. Treatment with 8b or 16b significantly inhibited the growth of HCC tumors in vivo. These data provide a proof-in-principle that furoxan/OA hybrids may be used for therapeutic intervention of human liver cancers.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18598019     DOI： 10.1021/jm800167u

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  9 in total

1.  Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

Authors:  Wenwen Duan; Jin Li; Elizabeth S Inks; C James Chou; Yuping Jia; Xiaojing Chu; Xiaoyang Li; Wenfang Xu; Yingjie Zhang
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

Review 2.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

3.  Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction.

Authors:  Xiang Gao; Baojia Sun; Yonglian Hou; Lilin Liu; Jianan Sun; Fanxing Xu; Dahong Li; Huiming Hua
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Hepatocarcinogenesis driven by GSNOR deficiency is prevented by iNOS inhibition.

Authors:  Chi-Hui Tang; Wei Wei; Martha A Hanes; Limin Liu
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

Review 5.  Discovery and development of natural product oridonin-inspired anticancer agents.

Authors:  Ye Ding; Chunyong Ding; Na Ye; Zhiqing Liu; Eric A Wold; Haiying Chen; Christopher Wild; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

6.  MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry.

Authors:  Wei Yu; Changshan Huang; Qian Wang; Tao Huang; Yuechao Ding; Chao Ma; Hongbo Ma; Weiyu Chen
Journal:  Tumour Biol       Date:  2014-08-03

7.  Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells.

Authors:  Zhiguang Ren; Xiaoke Gu; Bin Lu; Yaqiong Chen; Guojiang Chen; Jiannan Feng; Jizhen Lin; Yihua Zhang; Hui Peng
Journal:  J Cell Mol Med       Date:  2016-02-10       Impact factor: 5.310

8.  Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.

Authors:  Dahong Li; Lei Wang; Hao Cai; Yihua Zhang; Jinyi Xu
Journal:  Molecules       Date:  2012-06-18       Impact factor: 4.411

Review 9.  Heavy metal toxicity in plants and the potential NO-releasing novel techniques as the impending mitigation alternatives.

Authors:  Anjali Pande; Bong-Gyu Mun; Nusrat Jahan Methela; Waqas Rahim; Da-Sol Lee; Geun-Mo Lee; Jeum Kyu Hong; Adil Hussain; Gary Loake; Byung-Wook Yun
Journal:  Front Plant Sci       Date:  2022-09-23       Impact factor: 6.627
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.